@article {LoizziA131, author = {V Loizzi and E Cicinelli and F Arezzo and V Cataldo and M Mongelli and F Legge and G Cazzato and G Serio and L Resta and G Cormio}, title = {957 Prognostic factors in clear cell carcinoma of endometrium: analysis of 55 cases}, volume = {31}, number = {Suppl 3}, pages = {A131--A132}, year = {2021}, doi = {10.1136/ijgc-2021-ESGO.215}, publisher = {BMJ Specialist Journals}, abstract = {Introduction/Background*The purpose of this study was to evaluate the clinical and pathologic prognostic factors associated with survival in patients with clear cell carcinoma (CCC) of the endometrium.Methodology Retrospective review of endometrial clear cell carcinoma was conducted in order to evaluate the clinico-pathologic prognostic factors.Result(s)*Fifty-five patients were diagnosed with endometrial CCC. The median overall and disease-free survivals were 40 and 20 months, respectively. A univariate analysis was performed with respect to stage of disease, age, lymph nodes status, myometrium invasion, lymph vascular space invasion and adjuvant therapy. Stage was found to be the only important prognostic factor related to survival. In fact, early stage had a median survival of 77 months compared to 34 months in the advanced disease (p\<0.04). These differences remained significant after adjusting for single stage (stage III versus IV). However, no differences in survival were observed between stage I and II.Conclusion*Endometrial CCC is a rare histotype. Advanced stage disease is considered a poor prognostic factor. Recurrences are high even in early stage. Randomized clinical trials are needed.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/31/Suppl_3/A131.3}, eprint = {https://ijgc.bmj.com/content/31/Suppl_3/A131.3.full.pdf}, journal = {International Journal of Gynecologic Cancer} }